Jafarinia, Morteza

Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019

Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet

Global Health and EpidemiologyInsurance, Mortality, Demography, Risk Management

Cited by 19,358

Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet

Cardiovascular Health and Risk FactorsGlobal Health and Epidemiology

Cited by 9,854

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Ferrari, A. J., Santomauro, D. F., Aali, A., Abate, Y. H., Abbafati, C., Abbastabar, H., Abd ElHafeez, S., Abdelmasseh, M., Abd-Elsalam, S., Abdollahi, A., et al. (2024) · The Lancet

Global Health and EpidemiologyInsurance, Mortality, Demography, Risk Management

Cited by 5,112

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Naghavi, M., Ong, K. L., Aali, A., Ababneh, H. S., Abate, Y. H., Abbafati, C., Abbasgholizadeh, R., Abbasian, M., Abbasi-Kangevari, M., Abbastabar, H., et al. (2024) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Health and Epidemiology

Cited by 2,889

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

Schumacher, A. E., Kyu, H. H., Aali, A., Abbafati, C., Abbas, J., Abbasgholizadeh, R., Abbasi, M. A., Abbasian, M., Abd ElHafeez, S., Abdelmasseh, M., et al. (2024) · The Lancet

Insurance, Mortality, Demography, Risk ManagementCOVID-19 epidemiological studies

Cited by 1,045

Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Hay, S. I., Ong, K. L., Santomauro, D. F., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abate, B. B., Abbafati, C., et al. (2025) · The Lancet

Global Health and EpidemiologyCardiovascular Health and Risk Factors

Cited by 916

Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019

Lozano, R., Fullman, N., Mumford, J. E., Knight, M., Barthelemy, C. M., Abbafati, C., Abbastabar, H., Abd-Allah, F., Abdollahi, M., Abedi, A., et al. (2020) · The Lancet

Healthcare Systems and ReformsHealthcare Policy and Management

Cited by 719

Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023

Naghavi, M., Kyu, H. H., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abafita, B. J., Abaraogu, U. O., Abbafati, C., Abbasi, M., et al. (2025) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Health and Epidemiology

Cited by 595

Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023

Schumacher, A. E., Zheng, P., Barber, R. M., A, B., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abbafati, C., Abbas, N., et al. (2025) · The Lancet

Insurance, Mortality, Demography, Risk ManagementGlobal Cancer Incidence and Screening

Cited by 209

Mapping routine measles vaccination in low- and middle-income countries

Collaborators, L. B. O. D. V. C., Sbarra, A. N., Rolfe, S., Nguyen, J. Q., Earl, L., Galles, N. C., Marks, A., Abbas, K. M., Abbasi-Kangevari, M., Abbastabar, H., et al. (2021) · Nature

Vaccine Coverage and HesitancyVirology and Viral Diseases

Cited by 125

Does oral administration of ketamine accelerate response to treatment in major depressive disorder? Results of a double-blind controlled trial

Arabzadeh, S., Hakkikazazi, E., Shahmansouri, N., Tafakhori, A., Ghajar, A., Jafarinia, M., & Akhondzadeh, S. (2018) · Journal of Affective Disorders

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 89

Efficacy and safety of celecoxib monotherapy for mild to moderate depression in patients with colorectal cancer: A randomized double-blind, placebo controlled trial

Alamdarsaravi, M., Ghajar, A., Noorbala, A.-A., Arbabi, M., Emami, A., Shahei, F., Mirzania, M., Jafarinia, M., Afarideh, M., & Akhondzadeh, S. (2017) · Psychiatry Research

Treatment of Major DepressionCancer survivorship and care

Cited by 43

Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study

Jafarinia, M., Mohammadi, M., Modabbernia, A., Ashrafi, M., Khajavi, D., Tabrizi, M., Yadegari, N., & Akhondzadeh, S. (2012) · Human Psychopharmacology: Clinical and Experimental

Attention Deficit Hyperactivity DisorderPharmaceutical studies and practices

Cited by 42